Retreatment with First-Generation Selective RET Inhibitors in RET -Rearranged NSCLC Pretreated with Selpercatinib or Pralsetinib - Results from the RET-MAP Registry

Key Points

This research aims to evaluate the feasibility and clinical outcomes of retreating NSCLC patients with selective RET inhibitors after previous treatment failures.
Patients were pretreated with selpercatinib or pralsetinib.
Identified cases of toxicity leading to SRI switch were analyzed.
Observed outcomes post-rechallenge focusing on disease progression.
Switching SRI after toxicity is feasible and active in certain patient groups.
Overall efficacy of SRI rechallenge was limited.
Patients with brain-only or oligoprogressive disease showed some potential benefit.

Registry results demonstrate toxicity management and limited, but potential, efficacy in selective patients with NSCLC.

No abstract yet. The journal hasn't published one we can show.

No takes yet. Share an insight, caveat, or question.

Marinello et al. (2026) studied this question.

View at Publisher

Ask AI

Bookmark

Share